{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017035","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.094553+00:00","generated_at":"2026-05-26T23:54:08.776226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025","bullets":["Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.","Cash & securities $216.7M; expects runway into FY2028.","RSV zelicapavir Phase 2 RSVHR top-line data expected Q3 2025; Dec 2024 pediatric study showed antiviral effect.","Immunology: EPS-1421 KIT inhibitor IND studies ongoing; STAT6 candidate selection H2 2025; third program announced 2025.","Filed appeal in patent lawsuit against Pfizer over Paxlovid (Feb 3, 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017035","json":"https://secwatch.observer/filing/0000950170-25-017035.json","markdown":"https://secwatch.observer/filing/0000950170-25-017035.md","text":"https://secwatch.observer/filing/0000950170-25-017035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/0000950170-25-017035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017025017035/enta-20250210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:54:08.776226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}